Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration

• Status: Completed
• Trial end date: 2018-07-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate Ranibizumab as prophylaxis against the conversion to neovascular Age-Related Macular Degeneration

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Leonard Feiner, MD, PhD
• Collaborator: NJ Retina (Retina Associates of New Jersey)
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• Adults over 50 years old

• Able to sign informed consent and comply with the study protocol for the duration of the two years.

• Nonexudative age-related macular degeneration (AMD) in one eye (study eye) •At time of enrollment, fellow non-study eye must have recently diagnosed (not more than 2 years prior to enrollment), angiographically documented, previously untreated prior to diagnosis, CNV lesion (i.e., leakage on fluorescein angiography AND subretinal, intraretinal, or sub-RPE fluid on OCT) secondary to age-related macular degeneration.

Exclusion Criteria:

• Previous treatment with verteporfin PDT, Macugen®, Lucentis®, intravitreal Avastin®, intravitreal Eylea®, thermal laser, external beam radiation or other AMD therapy in the study eye.

• History of macular hole in study eye.

• History of vitrectomy in study eye.

• Lens extraction or implantation within the last 3 months.

• Capsulotomy within the last 1 month.

• Lens or other media opacity that would preclude good fundus photography or angiography within the next 2 years.

• Nevus > 2 disc areas within 3000 microns of the foveal center or with fluid or leakage on fluorescein angiography.

• Macular edema or signs of diabetic retinopathy more severe than 10 red dots (microaneurysms or blot hemorrhages).

• Retinal changes related to high myopia and no myopic correction greater than 8.00 diopters spherical equivalent [sphere + ½ cylinder].

• Any progressive ocular disease that would affect visual acuity within the next 2 years.

• Previous participation in any studies of investigational drugs likely to have ocular effects within 30 days preceding the initial study treatment.

• Concurrent use of systemic anti-VEGF agents.

• Active or recent (within 4 weeks) intraocular inflammation (grade trace or above) in the study eye.

• Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye.

• For subjects who have undergone prior refractive or cataract surgery in the study eye, the preoperative refractive error in the study eye cannot exceed 8 diopters of myopia.

• Uncontrolled glaucoma in the study eye (defined as intraocular pressure > 25 mmHg) despite treatment with antiglaucoma medication).

• Patients who are unable to be photographed to document CNV due to known allergy to fluorescein dye, lack of venous access or cataract obscuring the CNV.

• Patients with other ocular diseases that can compromise the visual acuity of the study eye such as amblyopia and anterior ischemic optic neuropathy.

• Current treatment for active systemic infection.

• Evidence of significant uncontrolled concomitant diseases such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders.

• History of recurrent significant infections or bacterial infections.

• Inability to comply with study or follow-up procedures.

• Pregnancy (positive pregnancy test) or lactation Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.

• Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated

• Participation in another simultaneous medical investigation or trial